atai Life Sciences B.V. is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai Life Sciences B.V. is based in BERLIN.
| Revenue (Most Recent Fiscal Year) | $0.31M |
| Net Income (Most Recent Fiscal Year) | $-149.27M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.04 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -7999.62% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -102.10% |
| Return on Assets (Trailing 12 Months) | -77.55% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.07 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.07 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.08 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.76 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.15 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.93 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.91 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 200.34M |
| Free Float | 137.83M |
| Market Capitalization | $464.78M |
| Average Volume (Last 20 Days) | 2.12M |
| Beta (Past 60 Months) | 1.22 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 31.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 28.41% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |